• Schindler TH, Anderson A, El Ghannudi S, Imperiale A. Identification and characterization of cardiac sarcoidosis with positron emission tomography. Eur J Clin Invest. 2022;52:e13722. Concise editorial of PET for the detection and characterization of cardiac sarcoidosis.
Article CAS PubMed Google Scholar
• Schindler TH, Solnes L. Role of PET/CT for the Identification of Cardiac Sarcoid Disease. Ann Nucl Cardiol. 2015;1:79–86. Comprehensive review of PET for the detection and characterization of cardiac sarcoidosis.
•• Kruse MJ, Kovell L, Kasper EK, Pomper MJ, Moller DR, Solnes L, et al. Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10:157–67. First study that demonstrates the potential added diagnostic value of PET-determined myocardial blood flow and treatment monitoring in cardiac sarcoidosis.
•• Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of (18)F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med. 2017;58:1341–53. Comprehensive position paper on the pathophysiology, clinical manifestation, outcome, and cardiovascular PET application in sarcoidosis.
Article CAS PubMed PubMed Central Google Scholar
Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305:391–9.
Article CAS PubMed Google Scholar
• Trivieri MG, Robson PM, Vergani V, Vergani V, LaRocca G, Romero-Daza AM, et al. Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2024;17(4):425–7. https://doi.org/10.1016/j.jcmg.2023.11.010. Online ahead of print. First study that demonstrates the important role of integrated PET/MR in outcome predition in cardiac sarcoidosis.
• Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on (18)F-FDG PET Scans for Suspected Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2018;11:336–45. Important study that demonstrates PET determined cardiac parameters as high risk predictors for cardiovascular outcome in sarcoidosis.
Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.
Article CAS PubMed Google Scholar
Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55:99–106.
Larson SR, Pieper JA, Hulten EA, Ficaro EP, Corbett JR, Murthy VL, et al. Characterization of a highly effective preparation for suppression of myocardial glucose utilization. J Nucl Cardiol. 2020;27:849–61.
Ohira H, Birnie DH, Pena E, Bernick J, Mc Ardle B, Leung E, et al. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2016;43:259–69.
Article CAS PubMed Google Scholar
•• Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac Sarcoidosis. Clin Chest Med. 2015;36:657–68. Comprehensive review on the pathophysiology, clinical manifestation, diagnosis, outcome, and treatment of cardiac sarcoidosis.
• Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36. First study that demonstrates the important role of FDG-PET in outcome predition in cardiac sarcoidosis.
Divakaran S, Stewart GC, Lakdawala NK, Padera RF, Zhou W, Desai AS, et al. Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2019;12:e008975.
Article PubMed PubMed Central Google Scholar
Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74.
Schindler TH, Dilsizian V. Coronary microvascular dysfunction: clinical considerations and noninvasive diagnosis. JACC Cardiovasc Imaging. 2020;13:140–55.
Schindler TH, Fearon WF, Pelletier-Galarneau M, Ambrosio G, Sechtem U, Ruddy TD, et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction. A JACC: Cardiovascular Imaging Expert Panel Statment. JACC Cardiovasc Imaging. 2023;16(4):536–48.
Verma A, Ramayya T, Upadhyaya A, Valenta I, Lyons M, Marschall J, et al. Post COVID-19 syndrome with impairment of flow-mediated epicardial vasodilation and flow reserve. Eur J Clin Invest. 2022;52:e13871.
Article CAS PubMed Google Scholar
Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36:2050–60.
Article CAS PubMed Google Scholar
Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018;39:840–9.
Article CAS PubMed Google Scholar
Selvaraj S, Seidelmann SB, Soni M, Soni M, Bhattaru A, Margulies KB, et al. Comprehensive nutrient consumption estimation and metabolic profiling during ketogenic diet and relationship with myocardial glucose uptake on FDG-PET. Eur Heart J Cardiovasc Imaging. 2022;23:1690–7.
Article PubMed PubMed Central Google Scholar
Selvaraj S, Margulies KB, Dugyala S, Schubert E, Tierney A, Pryma DA, et al. Comparison of exogenous ketone administration versus dietary carbohydrate restriction on myocardial glucose suppression: a crossover clinical trial. J Nucl Med. 2022;63:770–6.
CAS PubMed PubMed Central Google Scholar
Rojulpote C, Bhattaru A, Jean C, Adams SL, Patel V, Vidula MK, et al. Effect of immunosuppressive therapy and biopsy status in monitoring therapy response in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2022;15:1944–55.
留言 (0)